OBJECTIVE: To investigate the clinical characteristics of @entity3335 ( @entity3335 )-antineutrophil cytoplasmic antibody (ANCA) associated @entity1333 ( @entity3335 -AAV) with @entity651 and the relationship between @entity651 and ANCA against light chain of @entity3335 (LCMPO-ANCA). METHODS: A total of 195 @entity1 with newly diagnosed primary active @entity3335 -AAV were recruited in this prospective study. Indirect immunofluorescence assay was used to detect peri-nuclear ANCA (p-ANCA). Immunoblotting and ELISA were used to detect @entity3335 -antineutrophil cytoplasmic antibody ( @entity3335 -ANCA). Clinical features of @entity1 with both positive p-ANCA and @entity3335 -ANCA were collected. Disease activity was evaluated by Birmingham @entity1333 Activity Score- version 3 (BVAS-V3) Recombinant light chain of @entity3335 was used to coat substrate of LCMPO-ANCA by ELISA. The clinical characteristics of @entity651 and its correlation with serum levels of p-ANCA, @entity3335 -ANCA and LCMPO-ANCA were explored. RESULTS: All 195 @entity1 (64 male and 131 female), consisted of 191 @entity1 (98.0%) with microscopic @entity2883 , 3 @entity1 (1.5%) with @entity2883 with @entity2883 , and 1(0.5%) with eosinophilic @entity2883 with @entity2883 including 64 @entity1 and 131 @entity1 . Their mean age was (63.2  13.5) years old. The level of @entity3335 -ANCA had a positive correlation with general BVAS-V3 (r=0.193, P=0.007) in all @entity1 , and the level of LCMPO-ANCA was positively related with the pulmonary BVAS-V3 (r=0.228, P=0.001). As for multiple systemic damages, the incidence of lung involvement was 60.51% (118/195), which ranked second to renal involvement (71.80%, 140/195). The most common @entity651 represented as pulmonary infiltration of 80.51% (95/118), @entity1143 / pleurisy of 41.53% (49/118), pulmonary nodule or cavity of 22.03% (26/118). Compared with those without lung involvement, the @entity1 with @entity651 were older [(66.39  10.70) years old vs (58.30  15.72) years old; t=4.277, P=0.001], had a shorter course of disease [2.00(1.00,10.50) months vs 3.00(1.00,3.50) months; t=-2.283, P=0.024], and higher scores of general BVAS-V3 (18.21  6.08 vs 15.18  5.64; t=3.501, P=0.001). Also, in the @entity1 with @entity358 , the positive rate of LCMPO-ANCA was significantly higher (35.59% vs 6.49%;   (2)=21.569, P<0.001), and the level of LCMPO-ANCA was significantly higher (0.377  0.229 vs 0.285  0.079; t=3.399, P=0.001) than those without lung involvement. The pulmonary BVAS-V3 in the @entity1 with LCMPO-ANCA was significantly higher than that in the @entity1 without LCMPO-ANCA (4.34  2.10 vs 2.59  2.52; t=4.301, P<0.001), whereas the pulmonary BVAS-V3 was not correlated with LCMPO-ANCA (r=0.035, P=0.708) in @entity1 with @entity651 . CONCLUSION: @entity651 was relatively common and insidious in @entity1 with @entity3335 -AAV. To monitor ANCA level is necessary in @entity1 with @entity651 . LCMPO-ANCA might play an important role in the pathogenesis of @entity358 in AAV.

[A preliminary study of the significance of autoantibodies against light chain of @entity3335 on pulmonary damages in XXXX -antineutrophil cytoplasmic antibody associated @entity1333 ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion'] @entity3335 :: ('4353', 'Gene') :: ['MPO', 'myeloperoxidase'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis', 'vasculitis'] @entity651 :: ('MESH:D055370', 'Disease') :: ['Pulmonary injury', 'lung injuries', 'pulmonary injuries', 'pulmonary injury'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary lesions'] @entity2883 :: ('MESH:D014890', 'Disease') :: ['polyangiitis', 'granulomatosis']
@entity3335 :: (4353,Gene) :: ['myeloperoxidase']
